J. Golay

发表

New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation.

A. Mortellaro, S. Songia, P. Gnocchi, 1999, Journal of immunology.

BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo.

R. Valgardsdottir, J. Golay, R. Alzani, 2021, Cytotherapy.

Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.

N. Perico, G. Remuzzi, M. Marasà, 2011, Clinical journal of the American Society of Nephrology : CJASN.

Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate.

J. Golay, C. Rota, M. Morigi, 2011, Cytotherapy.

The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.

E. Clark, J. Golay, P. Beverley, 1985, Journal of immunology.

Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols

J. Golay, M. Introna, A. Rambaldi, 2014, Haematologica.

Frequent nonmalignant genetic alterations occurrence in clinical grade Mesenchymal Stromal Cells expanded for Cell Therapy Protocols

J. Golay, A. Rambaldi, O. Spinelli, 2014 .

Third‐party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial

N. Perico, G. Remuzzi, J. Golay, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

B Lymphocyte Surface Antigens Involved in the Regulation of Immunoglobulin Secretion

J. Golay, P. Beverley, F. Rawle, 1986 .

Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization

C. Castilletti, M. Capobianchi, R. Valgardsdottir, 2021, Antibodies.

Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets.

A. Mantovani, E. Erba, S. Taverna, 1997, Journal of immunology.

Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies.

J. Golay, D. Crawford, 1987, Immunology.

Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols

J. Golay, M. Introna, A. Rambaldi, 2014, Haematologica.

Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1

R. Valgardsdottir, J. Golay, M. Beeg, 2024, Antibodies.

Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab

R. Valgardsdottir, J. Golay, M. Introna, 2024, Antibodies.